Actively Recruiting
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Led by Henry Ford Health System · Updated on 2026-02-24
18
Participants Needed
1
Research Sites
362 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
CONDITIONS
Official Title
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with hematologic malignancy who require allogeneic stem cell transplant and have no matched related or unrelated donor
- Age between 18 and 70 years old
- Karnofsky performance score of at least 80%
- Adequate kidney function with creatinine clearance above 60 ml/min
- Adequate liver function with total bilirubin below 1.5 and liver enzymes below 2.5 times normal, no chronic active hepatitis or cirrhosis
- Negative Beta HCG test for women of childbearing potential
- Women of childbearing potential must agree to use effective contraception during the study
- Patient or legal representative able to provide informed consent
You will not qualify if you...
- Positive for HIV, hepatitis B surface antigen, hepatitis C virus, or other viral hepatitis or cirrhosis
- Active or prior central nervous system leukemia unless in remission for at least 2 months
- History of serious chronic mental disorders or drug abuse affecting treatment compliance
- Uncontrolled infections
- Presence of donor-specific antibodies
- Ejection fraction below 40%, history of heart failure, or cardiovascular disease
- History or current thrombosis, family history of thrombosis, severe obesity, or thrombophilia
- Previous hormone-responsive cancer
- History of seizures
- History of migraine or severe headaches
- History of asthma
- History of uterine fibroids
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Actively Recruiting
Research Team
S
shatha farhan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here